

Supplementary Online Content

Fakih M, Sandhu J, Lim D, Li X, Li S, Wang C. Regorafenib, ipilimumab, and nivolumab for patients with microsatellite stable colorectal cancer and disease progression with prior chemotherapy: a phase 1 nonrandomized clinical trial. *JAMA Oncol*. Published online March 9, 2023. doi:10.1001/jamaoncol.2022.7845

eTable 1. Nonimmune-Related Adverse Events

eTable 2. Detailed Characteristics of Patients

eFigure. Waterfall Plot of Tumor Responses and Molecular Characteristics

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Nonimmune-Related Adverse Events

Non-irAEs	RP2D cohort (n=29)			Dose optimization cohort (n=10)		
	Grade 2 n (%)	Grade 3 n (%)	Grade 4 n (%)	Grade 2 n (%)	Grade 3 n (%)	Grade 4 n (%)
Anemia	2 (6.9)	4 (13.8)	0 (0)	0 (0)	0 (0)	0 (0)
Thrombocytopenia	6 (20.7)	1 (3.4)	0 (0)	0 (0)	0 (0)	0 (0)
Palmar-plantar erythrodysesthesia syndrome	2 (6.9)	1 (3.4)	0 (0)	1 (10)	0 (0)	0 (0)
Fatigue	6 (20.7)	1 (3.4)	0 (0)	0 (0)	0 (0)	0 (0)
Neutropenia	1 (3.4)	1 (3.4)	0 (0)	0 (0)	0 (0)	0 (0)
Abdominal cramping	0 (0)	1 (3.4)	0 (0)	0 (0)	0 (0)	0 (0)
Proteinuria	4 (13.8)	0 (0)	0 (0)	1 (10)	0 (0)	0 (0)
Hypertension	1 (3.4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Nausea	1 (3.4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Leukopenia	4 (13.8)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Anorexia	1 (3.4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Hypocalcemia	1 (3.4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Hyponatremia	1 (3.4)	0 (0)	0 (0)	0 (0)	0 (0)	1 (10)

eTable 2. Detailed Characteristics of Patients

Patient	Primary tumor location	Metastatic pattern	RAS	BRAF ^{V600E}	PD-L1 Score	TMB (mut/Mb)	Response (RECIST)	Response (iRECIST)
001	Left	Lung, LNs, soft tissue	NRAS (G12D)	WT	1	3	SD	SD
002	Left	Liver, lung, LNs	KRAS (G12D)	WT	1	4	PD	PD
003	Left	Peritoneal carcinomatosis	WT	WT	0	11	PD	PD
004	Left	Lung	KRAS (G12D)	WT	NA	NA	SD	SD
005	Right	Lung, liver, LNs	KRAS (G12D)	WT	0	9.6	PD	PD
006	Left	Liver, Lung, adrenal, peritoneal nodules	NRAS (G12D)	WT	NA	NA	PD	PD
007	Left	Lung, liver serosal, LNs	WT	WT	NA	2	PD	PD
008	Left	Lung, LNs	KRAS (G12V)	WT	NA	9	PR	PR
009	Right	Lung	KRAS (G12V)	WT	NA	NA	PD	SD
010	Left	Lung	KRAS (G12D)	WT	NA	4	PR	PR
011	Right	Lung	WT	V600E	NA	NA	PR	PR
012	Right	Lung, LNs	WT	V600E	NA	2	PR	PR
013	Left	Vaginal	KRAS (G12D)	WT	NA	NA	SD	SD
014	Left	Skin, LNs	KRAS (G12V)	WT	NA	1	PD	PD
015	Left	Lung, Liver, LNs	KRAS (G13D)	WT	10	2	SD	SD
016	Left	LNs	KRAS (G12V)	WT	NA	1	PR	PR
017	Left	Pelvic	WT	WT	0	NA	SD	SD
018	Left	Lung, Liver	WT	WT	NA	NA	SD	SD
019	Left	Lung, Pelvic, LNs	WT	V600E	NA	3	PD	PR
020	Left	LNs, pelvic	KRAS (Q61R)	WT	0	1	PR	PR
021	Left	Liver, peritoneal carcinomatosis, cardiophrenic carcinomatosis, abdominal wall	KRAS (G12D)	WT	NA	1	PD	PD
022	Right	Lung, abdominal wall, peritoneal nodules	KRAS (G13D)	WT	NA	1	PD	SD
023	Right	Lung	KRAS (G12D)	WT	0	4	SD	SD
024	Right	Lung, LNs	KRAS (G13D)	WT	NA	NA	PR	PR
025	Left	Lung, LNs	KRAS (G12V)	WT	5	5	SD	SD
026	Right	Lung	KRAS (G12V)	WT	0	6	SD	SD
027	Left	Lung, Liver, Pelvic, bone	WT	WT	0	NA	SD	SD
028	Right	Lung	KRAS (G12D)	WT	NA	2	PR	PR
029	Left	Lung, LNs	WT	WT	NA	5	PD	PD

WT: wild type; PR: partial response; SD: stable disease; PD: progressive disease; LN: lymph node

eFigure. Waterfall Plot of Tumor Responses and Molecular Characteristics

